SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001171843-23-001548
Filing Date
2023-03-09
Accepted
2023-03-09 16:05:27
Documents
14
Period of Report
2023-03-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_030923.htm   iXBRL 8-K 14198
2 PRESS RELEASE exh_991.htm EX-99.1 59035
  Complete submission text file 0001171843-23-001548.txt   280878

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gnw-20190101.xsd EX-101.SCH 3069
4 XBRL DEFINITION FILE gnw-20190101_def.xml EX-101.DEF 25640
5 XBRL LABEL FILE gnw-20190101_lab.xml EX-101.LAB 34011
6 XBRL PRESENTATION FILE gnw-20190101_pre.xml EX-101.PRE 22139
8 EXTRACTED XBRL INSTANCE DOCUMENT f8k_030923_htm.xml XML 3139
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Filer) CIK: 0001799448 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39617 | Film No.: 23719717
SIC: 2836 Biological Products, (No Diagnostic Substances)